News
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Hardman & Co Research: Tissue Regenix (TRX): Restructured to satisfy product demand
Hardman & Co Research: Tissue Regenix (TRX): Restructured to satisfy product demand
Hardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult
Hardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
DGAP-News: Ergomed plc: Lewis Cameron, ehemals Leiter der globalen klinischen Entwicklung bei Covance, zum Chief Operating Officer ernannt
DGAP-News: Ergomed plc: Lewis Cameron, ehemals Leiter der globalen klinischen Entwicklung bei Covance, zum Chief Operating Officer ernannt
Hardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
Hardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
Hardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
Hardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Form 8.3 - The Vanguard Group, Inc.: Consort Medical plc
Hardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
Hardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
3 Dividend Stocks to Double Up on Right Now
The recent 50-basis-point rate cut by the Federal Reserve is a double-edged sword for investors. They probably like that it makes more projects economical, which should presumably increase profits
Is AT&T the Right Stock for Retired Investors Now That the Fed Has Cut Rates?
The Federal Reserve's recent 50-basis-point cut to interest rates marks the beginning of what could be steadily declining rates over the coming months. It will become harder to find a good payout
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Investors looking for stocks that can provide dramatic gains found what they were looking for with a pair of cancer drug developers. From the end of 2023 through the closing bell on Sept. 23, shares